Detalles de la búsqueda
1.
Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Mol Pharm
; 15(8): 3260-3271, 2018 08 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29944378
2.
RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells.
Curr Cancer Drug Targets
; 23(2): 103-117, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36028965
3.
Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability.
Cell Rep
; 42(12): 113503, 2023 12 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38019654
4.
Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase.
Curr Cancer Drug Targets
; 22(4): 312-327, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34951367
5.
Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer.
Drug Discov Today
; 25(7): 1160-1173, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32479905
6.
Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.
Ther Adv Med Oncol
; 12: 1758835920920069, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32426050
7.
Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
J Immunother Cancer
; 7(1): 250, 2019 09 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31519211
8.
Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
J Immunother Cancer
; 7(1): 75, 2019 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-30871619
9.
Correction to: Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
J Immunother Cancer
; 7(1): 94, 2019 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30940188
10.
RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
Mol Cancer Ther
; 17(12): 2654-2664, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30275241
Resultados
1 -
10
de 10
1
Próxima >
>>